Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Multi-omics reveal critical roles of phosphatidylcholine and sphingomyelin in antipsychotic efficacy for schizophrenia

Fig. 1

Flow diagram and flowchart. a Flow diagram of the multi-omics cohort. b Flowchart of the study. First, in the multi-omics cohort, subjects treated with 6-week paliperidone were divided into treatment responder and non-responder groups. Baseline genomic, proteomic, and metabolomic markers associated with antipsychotic efficacy were then explored using GWAS, differential analysis, and machine learning. Multi-omics enrichment was employed to investigate biological pathways affecting the response to antipsychotics. Subsequently, detailed analysis of these pathways identified key molecules related to antipsychotic efficacy. Finally, the association between these key molecules and treatment efficacy was validated in external cohorts by plasma and brain metabolite PRS. GWAS genome-wide association study, PC phosphatidylcholine, PRS polygenic risk score, SM sphingomyelin

Back to article page